Conditions: Fungal Infection
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 121
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.

Detailed description:

Arms:
arm 1: caspofungin acetate (MK0991) arm 2: Micafungin sodium

Interventions: intervention 1: caspofungin acetate intervention 2: Comparator: Micafungin sodium
Intervention descriptions: intervention 1: Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis. intervention 2: Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.

Protocol document: